KRAS and cancer: As a converse correlate to our findings, a study by Kumagaiin and colleagues demonstrated that lactic acid production resulting from Myc‐mediated LDHA upregulation was associated with anti‐PD‐1 treatment resistance.[36] Together, we concluded that KRAS inhibition or blockade of lactic acid production represents an exploitable approach to improve cancer immunotherapies.